Introduction
Colon cancer is the second most common cause of cancer deaths in both men and women in the US. With current therapeutic strategies, the 5-year survival rate of those with metastatic cancer is between 8% and 12% (1) . To address this issue, a number of studies are focused on the search for new and more effective therapy targets. The Prostate apoptosis response protein-4 (Par-4) is a pro-apoptotic protein that was first identified in prostate cancer cells undergoing apoptosis. can increase susceptibility of cancer cells to apoptotic agents such as doxorubicin, tumor necrosis factor alpha (TNF-α), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (2) (3) (4) . The down-regulation of Par-4 has been proposed to be a critical event in tumorigenesis (5) .
Par-4 is down-regulated in a number of human cancers, namely, endometrial (6) , renal cell carcinoma (3), pancreatic (7), lung (8) , and colon cancer (9) . Furthermore, Par-4 has been shown to be inactivated by Akt1 in human cancers, as well as in normal lung embryonic epithelial cells (6, 10) . In a number of cell lines, its overexpression is sufficient to induce apoptosis (10) (11) (12) . In others, increasing Par-4 levels does not cause cell death but increases the apoptotic effect of cell death stimuli (4, 10, 13, 14) .
Par-4 activity leads to apoptosis via both intrinsic and extrinsic pathways (15) (16) (17) . Intrinsic pathways include inhibiting transcriptional regulation by NFκB (5, 11, 16) . The extrinsic pathway involves the activation of TRAIL. In this case, Par-4 exhibits bystander effects, in that cells overexpressing Par-4 can secrete the protein and induce sensitivity to chemotherapy to nearby cancer cells that do not overexpress Par-4 (15) . The phosphorylation of Par-4 by Akt1
Research.
on July 12, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 9, 2011; DOI: 10.1158/1078-0432.CCR- enables the scaffolding protein 14-3-3 to bind Par-4, causing retention in the cytoplasm (18) .
Inhibition of Akt1 can result in activated Par-4 and sensitization to apoptotic stimuli.
The PI3K/Akt pathway, together with its associated negative regulator PTEN, is one important signal transduction pathway for chemoprevention and cancer treatment studies. Evidence supporting the importance of the PI3K/Akt signaling pathway in cancer chemoprevention and therapy has been well documented in literature (19) (20) (21) (22) , and has led to development of Akt signaling pathway inhibitors that are able to reduce tumor growth successfully. The entire pathway is deregulated in many human cancers, either by activating mutations, or by deletion of PTEN (23, 24) . Specifically, in colon cancer, Akt over-expression has been shown in 57% of sporadic colon tumors, higher than in many cancers, and upregulation occurs at a pre-malignant stage (25) . Moreover, activation of Akt has been shown in colon cancer cells but not in normal mucosa (25, 26) . In this study we used a new inhibitor of Akt, phenylbutyl isoselenocyanate (Ph-(CH 2 ) 4 -N=C=Se; ISC-4) (27, 28) , alone and in combination with Par-4, to effect colon tumor regression. ISC-4 was recently developed in our laboratories (28) through extensive structureactivity studies based on naturally occurring phenylalkyl isothiocyanates (Ph-(CH 2 ) n -N=C=S; ITCs), that have been shown to be effective at inhibiting Akt signaling pathways. In both epidemiological and laboratory investigations, naturally occurring and synthetic ITCs are well established anti-cancer agents for cancers at a variety of organ sites (29) (30) (31) (32) (33) (34) (35) (36) (37) . The lead compounds were optimized and the best Akt inhibitors were obtained by the isosteric replacement of sulfur in ITCs by selenium leading to isoselenocyanate derivatives (Ph-(CH 2 ) nN=C=Se). The rationale for this modification was based on the observation that organoselenium compounds have been shown to be effective in retarding tumorigenesis of several cancer types, including colon cancer (38) (39) (40) (41) (42) , in both animal models and epidemiological studies. In addition, it has been demonstrated that most cancer patients, including colon cancer patients (43, 44) , have lower serum selenium levels than healthy controls. Hence, ISC compounds combined the anticancer properties of both selenium and ITCs. ISC-4 designed by increasing the alkyl chain length and replacing sulfur by selenium in naturally occurring ITCs was identified as the most potent drug-like PI3K/Akt inhibitor (27, 28) . (BioRad, Hercules, CA). Membranes were blocked with 5% non-fat dry milk for 2 h and incubated with primary antibody overnight. The blots were washed 3X in TBS-Tween and incubated for 1 h in appropriate HRP-conjugated secondary antibodies (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Blots were washed and developed using the ECL chemiluminescent kit (Amersham, Piscataway, NJ, USA). The blots were exposed to autoradiography film and scanned.
Materials and Methods

Reagents
Cell viability assay
Human colon cancer cells were seeded in a 96 well plate were treated with 3. Inc., Bannockburn, IL). To avoid crosstalk between the two channels, sequential scanning of the tissue sample mounts was done.
Statistical methods
The statistical software program R version 2.11.1 (http://www.r-project.org/) was used to perform the statistical analysis. A repeated measures analysis of variance was used to test for an overall significance in treatment effect as well as at individual concentrations of the treatments for the in vivo studies. A two-sample t-test with unequal variances was used to test two individual treatments at specified concentrations. The robust Mann-Whitney two-sample nonparametric test was calculated for comparisons. The IC50 values were computed with the drc (Analysis of dose-response curves), package (version 2.1.1) using R (version 2.12.2) (47, 48).
Samples were normalized to the WT cells treated with DMSO only in each experiment.
Results
ISC-4 induces cell death in Human colon cancer cells
Akt inhibitors have been well studied as therapeutic options for cancer treatment. As a downstream target of Akt1, Par-4 may play a role in this process. ISC-4 ( Fig. 1A ) induces apoptosis at very low concentrations in cancer cells but not in normal cells (27) . We investigated the relative potency of ISC-4 and the sulfur analog, phenylbutyl isothiocyanate (PBITC), with a commercially available Akt inhibitor, API2, in HT29 cells ( A number of human colon cancer cell lines, HCT116, HT29, KM12C, SW480, and SW620, were compared for relative sensitivity to ISC-4. In all cases ISC-4 inhibited cell growth in a dose dependent manner at the concentrations tested, with IC50s of 9.15, 8.05, 13.07, 11.79, and 9.31, respectively (Fig. 1C) , indicating that the effect of ISC-4 is not specific to only one or two colon cancer cell lines. The levels of Par-4 and phospho-Akt (pAkt) proteins were compared by Western blot analysis between cell lines, and correlated to the sensitivity of the cells to ISC-4.
While there is little variation in the Par-4 levels of these cells, the amount of pAkt varies more widely. The upper band present most notably in HT29 and SW620 represents the Akt1 isoform. (Fig. 1C) . Inhibition of this protein would be expected to result in activation of Par-4, sensitizing the cells to apoptosis. However, it is difficult to say from this data that the pAkt levels affect sensitivity to ISC-4.
ISC-4 was shown previously to increase the binding of Par-4 to NFκB and decrease the binding to 14-3-3, indicating that ISC-4 causes inhibition of Akt1 and subsequent activation of Par-4 (45) . As our earlier data on Par-4 was collected using the rat par-4 gene, the in vivo experiments in this study were performed using the same cells transfected for continuity. We transfected (Fig. 1D) .
A repeated measures analysis of variance was used to compare overall effects of the Mock and Par-4 treatments yielding a statistically significant effect due to treatment (p=.0141) and concentration level (p=.0017), with no significant interaction effect (p=.7686). The individual significant differences between clones were analyzed with a two sided T-Test, and were only observed at the higher concentrations of 12.5 μM and 6.25 μM for the two human Par-4 clones.
ISC-4 reduces tumor growth in nude mice
As ISC-4 inhibits tumor cell viability but not normal cell viability in vitro (27) 
Wild type tumors in mice were examined prior to administration of therapeutic drugs. At 7 days after injection of cells, the tumors were measured and volumes calculated. All tumors growing from WT cells in mice with no other tumor were larger than every WT tumor growing in a mouse that had also been implanted with Par-4 overexpressing cells (Fig. 3A) . Similar results were obtained when the experiment was repeated. The tumor volume ratio of WT only/WT with Par-4 in the same mouse in the first experiment was 1.8, while in the second experiment the ratio was 2.0. Furthermore, at the time of euthanasia, the size of the WT tumors growing in the mice was inversely proportional to the size of the Par-4 tumor growing in the same mouse, indicating a dose dependent bystander effect of Par-4 overexpressing cells on WT cells (Fig. 3B ). This also indicates that the bystander effect functions effectively in distally growing tumors.
To examine the role of Par-4 with both treatment elements, ISC-4 and 5-FU, the wild type tumors in all mice with both treatments were compared. The wild type tumors in mice that also had Par-4 tumors grew significantly more slowly than did the wild type tumors growing alone in mice (Fig. 3C) 
ISC-4 downregulates Akt1 in mouse tumors
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